GBI Research, a leading business
intelligence provider, has released its latest research report "Cystic
Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators
Initiate Drive towards Personalized Treatment and Market Growth". The
value of the Cystic Fibrosis (CF) market is expected to increase significantly
in value over the forecast period across the leading eight developed nations,
from $695.6 million in 2012 to almost $4.5 billion in 2019. This equates to a
Compound Annual Growth Rate (CAGR) of 30.4%. Novel treatments with
disease-modifying mechanisms of action are the primary factor driving the
growth of the value of the market. The positive impact of new market entrants
will offset the effects of key patent losses during the forecast period.
View
Full Report with TOC @ http://www.radiantinsights.com/research/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth
Cystic Fibrosis Transmembrane
conductance Regulators (CFTR) modulators are the first type of CF therapy to
treat the root cause of the disease rather than the symptoms, and as a result,
they offer patients improved relief and quality of life. Kalydeco (ivacaftor),
which has been marketed since 2012, was the first CFTR modulator to reach the
market, and despite only treating a small proportion of the CF population, it
had a large impact on the value of the market. This effect will be repeated on
a larger scale when lumacaftor and Ataluren (PTC124) enter the market, as these
treatments can be used for a much larger proportion of the CF population.
Vertex Pharmaceuticals Inc. are the developers of Kalydeco, lumacaftor and
other early phase CFTR modulators, and are therefore expected to play a key
role in the development of the future CF market.
The
pricing of CFTR modulators will be premium due to the clinical benefits and
disease-modifying effects that they represent. Symptomatic therapies will be
used in conjunction with CFTR modulators, and will still be a necessary part of
the CF treatment plan. The antibiotics segment in particular is expected to
become overcrowded and competitive over the forecast period, due to cheap,
generic tobramycin products and novel market entrants competing for market
share.
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More
Information, Visit Radiant
Insights
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Email:
sales@radiantinsights.com
Blog
URL: http://radiantinsights.weebly.com/
No comments:
Post a Comment